Acorda Therapeutics, Inc. (ACOR) Financials

NASDAQ Currency in USD Disclaimer

$0.66

north_east NA Past Year
Day's range
$0.61
Day's range
$0.85

ACOR Income statement / Annual

Last year (2023), Acorda Therapeutics, Inc.'s total revenue was $117.63 M, a decrease of 0.79% from the previous year. In 2023, Acorda Therapeutics, Inc.'s net income was -$252.85 M. See Acorda Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Operating Revenue $117.63 M $118.57 M $129.07 M $152.97 M $192.41 M $471.43 M $588.29 M $519.60 M $492.66 M $401.48 M
Cost of Revenue $46.05 M $30.33 M $40.79 M $33.51 M $34.85 M $99.31 M $135.71 M $108.11 M $92.93 M $80.62 M
Gross Profit $71.59 M $88.23 M $88.28 M $119.45 M $157.56 M $372.12 M $452.57 M $411.49 M $399.73 M $320.87 M
Gross Profit Ratio 0.61 0.74 0.68 0.78 0.82 0.79 0.77 0.79 0.81 0.8
Research and Development Expenses $5.15 M $5.80 M $10.42 M $23.01 M $60.08 M $106.38 M $166.11 M $203.44 M $149.21 M $73.47 M
General & Administrative Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $172.25 M $181.62 M $235.44 M $205.63 M $201.81 M
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 -$320,000.00 -$17.55 M $0.00 $0.00
Selling, General & Administrative Expenses $89.70 M $106.26 M $124.40 M $152.58 M $192.85 M $172.25 M $181.30 M $217.89 M $205.63 M $201.81 M
Other Expenses $51,000.00 $18.21 M $30.76 M $30.76 M $25.64 M -$18.06 M -$19.07 M -$6.29 M -$14.62 M -$8.38 M
Operating Expenses $94.85 M $130.27 M $165.58 M $206.35 M $278.56 M $278.64 M $347.40 M $421.32 M $354.84 M $275.28 M
Cost And Expenses $140.90 M $160.60 M $206.37 M $239.86 M $313.41 M $377.95 M $483.12 M $529.43 M $447.77 M $355.90 M
Interest Income $530,000.00 $1.91 M $5,000.00 $816,000.00 $4.17 M $3.52 M $136,000.00 $339,000.00 $440,000.00 $674,000.00
Interest Expense $31.53 M $28.29 M $30.04 M $30.57 M $21.87 M $21.60 M $18.66 M $16.53 M $15.47 M $9.29 M
Depreciation & Amortization $31.67 M $32.01 M $32.50 M $21.94 M $25.64 M $11.48 M $23.23 M $21.58 M $15.01 M $8.47 M
EBITDA $8.40 M -$10.03 M -$44.80 M -$64.96 M $40.18 M $148.49 M $443.15 M $16.32 M $55.79 M $54.77 M
EBITDA Ratio 0.07 -0.08 -0.35 -0.42 0.21 0.31 0.75 0.03 0.11 0.14
Operating Income Ratio -0.2 -0.35 -0.6 -0.57 0.08 0.08 -0.4 -0.07 0.07 0.09
Total Other Income/Expenses Net -$272.76 M $6.54 M -$15.15 M -$1.46 M -$157.64 M -$18.06 M -$19.07 M -$32.49 M -$14.62 M -$8.38 M
Income Before Tax -$296.02 M -$35.25 M -$109.07 M -$107.67 M -$274.25 M $20.42 M -$251.89 M -$42.27 M $19.37 M $28.01 M
Income Before Tax Ratio -2.52 -0.3 -0.85 -0.7 -1.43 0.04 -0.43 -0.08 0.04 0.07
Income Tax Expense -$43.17 M $30.67 M -$5.12 M -$8.07 M -$1.28 M -$13.26 M -$28.53 M -$6.67 M $8.31 M $10.34 M
Net Income -$252.85 M -$65.92 M -$103.95 M -$99.59 M -$272.97 M $33.68 M -$223.36 M -$34.62 M $11.06 M $17.67 M
Net Income Ratio -2.15 -0.56 -0.81 -0.65 -1.42 0.07 -0.38 -0.07 0.02 0.04
EPS -203.59 -66.9 -195.75 -246.4 -689.42 85.98 -582.69 -91.79 31.42 51.53
EPS Diluted -203.59 -66.9 -195.75 -246.4 -689.42 85.38 -583.2 -91.79 30 50.4
Weighted Average Shares Out $1.24 M $985,350.00 $531,050.00 $404,199.00 $395,933.00 $391,750.00 $382,988.00 $377,158.00 $363,508.00 $350,634.00
Weighted Average Shares Out Diluted $1.24 M $985,350.00 $531,050.00 $404,199.00 $395,933.00 $394,508.00 $383,325.00 $377,158.00 $368,600.00 $354,533.00
Link